ZBIO: Zenas Biopharma Inc Growth-Adjusted Market Cap to Net Income
International patent protection risks and logistical barriers are exerting pressure on Zenas Biopharma Inc (ZBIO). Analyzing the PEG ratio trajectory on GURU.Markets, we see that 0.00 expresses the metric's current value. This highlights the potential of multispecific antibodies for inflammation therapy and the implementation of robotic bio-screening, which accelerates the development of new drugs within the company's laboratories.
Metric breakdowns and analytics for Zenas Biopharma, Inc. (ZBIO)
- share price and consensus valuation forecast:
- market capitalization information:
- company book value details:
- issuer credit burden and liquidity indicators:
- business earnings and investment ratios data:
ZBIO - Company Net Income|Net Profit Forecast Zenas Biopharma Inc|ZBIO - P/E Multiple|Forward P/E Multiple zenasbio.com|ZBIO - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio Zenas Biopharma Inc|ZBIO - Operating profit before deduction of amortization|Earnings per share for the trailing year Zenas Biopharma|ZBIO - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months zenasbio.com|ZBIO - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Zenas Biopharma Inc
- total revenue and sales volume data:
General company analysis:ZBIO - Zenas Biopharma Inc
This indicator compares market capitalization with earnings dynamics, allowing for the determination of the asset's degree of undervaluation relative to its expansion. An analysis of the P/E ratio adjusted for EPS growth confirms the efficiency of Zenas Biopharma Inc (ZBIO) management's resource allocation across global clinical programs, transforming biotech development potential into sustainable fundamental value for the company.
Who Zenas Biopharma Inc competes with
ARGX (Argenx) - Growth-Adjusted Payback Ratio|PEG Multiple BNTX (biontech.de)|Growth-Adjusted Market Cap to Net Income Abivax S.A. (ABVX)|ADMA - Price/Earnings to Growth Ratio|Protagonist Therapeutics, Inc. (PTGX) - Price/Earnings to Growth Multiple|Immunovant Therapeutics (IMVT) - Price/Earnings to Growth Ratio|Price/Earnings to Growth Multiple Kiniksa Pharmaceuticals|Price/Earnings to Growth Multiple GRFS|PEG Multiple adaptivebiotech.com|Price/Earnings to Growth Ratio Celldex (CLDX)|Aurinia Pharmaceuticals Inc. - Growth-Adjusted P/E Ratio|PEG Multiple BCRX (biocryst.com)|Vera Therapeutics, Inc. (VERA) - Price to Earnings Adjusted for Growth Rate|Dianthus Therapeutics, Inc. - PEG Multiple|Market Cap to Earnings and Growth Ratio PHVS|ABCL: PEG Multiple|Price to Earnings Adjusted for Growth Rate Tourmaline Corp (TRML)|PGEN (precigen.com) - PEG Multiple|PEG Multiple Pharming Corp|Price/Earnings to Growth Multiple NKTR (Nektar)|UPB (Upstream Bio Inc) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Immunome Corp IMNM|PEG Multiple Gossamer Bio Inc GOSS|KALV - Price/Earnings to Growth Ratio|Growth-Adjusted Payback Ratio SEPN (Septerna Pharma)|PVLA (Pieris Pharmaceuticals) - Price/Earnings to Growth Multiple|Savara Inc. - Growth-Adjusted Payback Ratio|RIGL (Rigel Pharmaceuticals, Inc.) - PEG Multiple|Price/Earnings to Growth Ratio ANAB|PEG Multiple ATXS|ENGN - Price to Earnings Adjusted for Growth Rate|PEG Multiple RAPT (rapt.com)|Company Value to Earnings Growth Ratio JBIO (Aerovate)|Aclaris Therapeutics, Inc - PEG Multiple|Price to Earnings Adjusted for Growth Rate Kyverna Therapeutics Inc.|TLSA: PEG Multiple|CABA - Growth-Adjusted Market Cap to Net Income|VTYX (ventyxbio.com) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Theratechnologies Inc. THTX|Price/Earnings to Growth Multiple AVTX (avalotx.com)|Price/Earnings to Growth Multiple Eledon Pharmaceuticals, Inc. ELDN|Price/Earnings to Growth Ratio Agenus, Inc AGEN|Climb Bio Inc - Price/Earnings to Growth Ratio|Zura Bio Limited - PEG Multiple|Growth-Adjusted Market Cap to Net Income aTyr Pharma, Inc. ATYR|ADAG: PEG Multiple|Market Cap to Earnings and Growth Ratio IMA (ImageneBio)|Price/Earnings to Growth Multiple STTK|EQ: Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Connect Pharma (CNTB)|PEG Multiple Immunic Therapeutics (IMUX)|PEG Multiple ATRA (Atara Biotherapeutics)|Growth-Adjusted Payback Ratio IFRX|XFOR (X4 Pharma) - Price to Earnings Adjusted for Growth Rate|Growth-Adjusted Payback Ratio ACET (adicetbio.com)|CELU: PEG Multiple|inmunebio.com (INMB) - PEG Multiple|BRNS (Barinthus Biotherapeutics PLC) - PEG Multiple|KZR: Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio SAB Biotherapeutics, Inc. (SABS)|AKTX (Akari Therapeutics plc) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Enlivex Therapeutics Ltd ENLV|QTTB - Price/Earnings to Growth Multiple|geovax.com - PEG Multiple|Growth-Adjusted Payback Ratio EDSA (Edesa Biotech Inc)|IBIO: PEG Multiple|Carisma Tx (CARM) - PEG Multiple|XTLB (XTL Biopharmaceuticals) - PEG Multiple|BOLT: Growth-Adjusted Payback Ratio|Price/Earnings to Growth Multiple HCWB (HCW Biologics, Inc.)|PEG Multiple Aptevo (APVO)|PEG Multiple AIM (aimimmuno.com)|PEG Multiple Aditxt Corp ADTX|GRI: Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio XRTX (xortx.com)|Vyome Holdings Inc. (HIND) - Price/Earnings to Growth Ratio|Revelation Bio (REVB) - PEG Multiple|INDP (Indaptus Corp) - PEG Multiple|SCNI: Growth-Adjusted Payback Ratio|PEG Multiple CALI|Price/Earnings to Growth Multiple Affimed N.V. AFMD|Price/Earnings to Growth Ratio Allakos ALLK|HOOK: Growth-Adjusted P/E Ratio|IGMS - Price/Earnings to Growth Ratio|Growth-Adjusted Market Cap to Net Income iTeos Therapeutics ITOS|Ocean Biomedical (OCEA) - Price/Earnings to Growth Ratio|tcbiopharm.com (TCBP) - PEG Multiple|THRD (Third Harmonic Bio Inc.) - PEG Multiple
